VEGFA and wet macular degeneration: mAbs have revolutionized the treatment of ophthalmic conditions (e.g., use of anti-vascular endothelial growth factor (VEGF) medicines such as ranibizumab (Lucentis®) in the treatment of wet age-related macular degeneration, AMD) [6].